The inhibition of the reverse transcriptase enzyme has played a critical role in the treatment and prevention of HIV from the earliest days of the epidemic through to the present.
Although current antiretroviral (ARV) therapies effectively control HIV in the majority of patients, unmet needs remain, including reduced toxicity, improved dosing, more convenient delivery, and long-term prevention of resistance. In the absence of an effective HIV vaccine and/or a cure regimen, it is imperative that ARV drug pipelines continue to pursue new and improved options.
Important new data on next generation reverse transcriptase inhibitors (RTIs) is being presented and published at an increasingly rapid rate. This 3-hour virtual program offered an educational opportunity for healthcare practitioners to both revisit the history of RTIs and become informed of recent developments in the field. In particular, this program will present and discuss preclinical and clinical information regarding 3 classes of RTIs: NRTIs, NNRTIs, and NRTTIs.
